Compare TNK & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TNK | ADPT |
|---|---|---|
| Founded | 2007 | 2009 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 2.5B |
| IPO Year | 2007 | 2019 |
| Metric | TNK | ADPT |
|---|---|---|
| Price | $74.34 | $14.44 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 9 |
| Target Price | ★ $77.00 | $17.78 |
| AVG Volume (30 Days) | 552.8K | ★ 1.5M |
| Earning Date | 01-01-0001 | 05-05-2026 |
| Dividend Yield | ★ 2.79% | N/A |
| EPS Growth | N/A | ★ 63.89 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $276,976,000.00 |
| Revenue This Year | N/A | $3.98 |
| Revenue Next Year | N/A | $22.72 |
| P/E Ratio | $8.05 | ★ N/A |
| Revenue Growth | N/A | ★ 54.77 |
| 52 Week Low | $33.35 | $6.26 |
| 52 Week High | $82.24 | $20.76 |
| Indicator | TNK | ADPT |
|---|---|---|
| Relative Strength Index (RSI) | 58.58 | 34.19 |
| Support Level | $42.26 | $12.32 |
| Resistance Level | $82.24 | $17.72 |
| Average True Range (ATR) | 2.88 | 0.71 |
| MACD | -0.56 | -0.08 |
| Stochastic Oscillator | 33.39 | 7.52 |
Teekay Tankers Ltd is a provider of marine services to the international oil and natural gas industries and an operator of medium-sized oil tankers. The company operates in two segments: Tankers, which consists of the operation of all of the company's tankers (including the operations from those tankers employed on full service lightering contracts), and the company's U.S. based ship-to-ship support service operations (including its lightering support services provided as part of full service lightering operations); and Marine Services, which consists of operational and maintenance marine services provided to the Australian government, Australian energy companies and other third parties. The company generates the majority of its revenue from the Tankers segment.
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).